LIVN vs NPCE
LIVN: LivaNova is a medical technology company specializing in innovative cardiovascular and neuromodulation therapies to improve patient lives. NPCE: NeuroPace makes the RNS System, the only FDA-approved brain-responsive neuromodulation device that monitors and treats drug-resistant epilepsy by delivering personalized electrical stimulation directly at seizure sources.
Side-by-side fundamentals
| Metric | LIVN | NPCE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $78.27 | $14.58 | |
| Market cap as of 2026-07-23 | $4.3B | $497M | |
| P/E as of 2026-07-23 | 40.32 | n/a | |
| PEG as of 2026-07-23 | 3.92 | n/a | |
| Net margin as of 2026-07-23 | +7.5% | -21.7% | LIVN higher |
| Gross margin as of 2026-07-23 | +67.5% | +78.3% | NPCE higher |
| Operating margin as of 2026-07-23 | +13.1% | -17.3% | LIVN higher |
| ROE as of 2026-07-23 | +9.1% | -120.7% | LIVN higher |
| ROA as of 2026-07-23 | +4.2% | -20.6% | LIVN higher |
| Debt / equity as of 2026-07-23 | 0.24 | 4.08 | LIVN lower |
| Revenue growth (YoY) as of 2026-07-23 | +12.4% | +18.1% | NPCE higher |
| Revenue CAGR (3y) SEC XBRL | +10.8% | +30.0% | NPCE higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.88 | 1.96 | |
| 1-year return as of 2026-07-22 close | +79.7% | +65.2% | LIVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.